The Role of Molecular Forms of Prostate-Specific Antigen (PSA or hK3) and of Human Glandular Kallikrein 2 (hK2) in the Diagnosis and Monitoring of Prostate Cancer and in Extra-Prostatic Disease

REFERENCES

• Schedlich LJ, Bennetts B, Morris BJ. Primary structure of a human glandular kallikrein gene. DNA 1987; 6: 429–437.
   Google Scholar
• Riegman PH, Vlietstra RJ, van der Korput J, et al. Characterization of the prostate-specific antigen gene: a novel human kallikrein-like gene. Biochem Biophys Res Commun 1989; 159: 95–102.
   Google Scholar
• Riegman PH, Vlietstra RJ, Klaassen P, et al. The prostate-specific antigen gene and the human glandular kallikrein-1 gene are tandemly located on chromosome 19. FEBS Lett 1989; 247: 123–126.
   Google Scholar
• Riegman PH, Vlietstra RJ, Suurmeij L, et al. Characterization of the human kallikrein locus. Genomics 1992; 14: 6–11.
   Google Scholar
• Fukushima D, Kitamura N, Nakanishi S. Nucleotide sequence of cloned cDNA for human pancreatic kallikrein. Biochemistry 1985; 24: 8037–8043.
   Google Scholar
• Clements JA. The glandular kallikrein family of enzymes: tissue-specific expression and hormonal regulation. Endocr Rev 1989; 10: 393–419.
   Google Scholar
• Chapdelaine P, Paradis G, Tremblay RR, et al. High level of expression in the prostate of a human glandular kallikrein mRNA related to prostate-specific antigen. FEBS Lett 1988; 236: 205–208.
   Google Scholar
• Henttu P, Lukkarinen O, Vihko P. Expression of the gene coding for human prostate-specific antigen and related hGK-1 in benign and malignant tumors of the human prostate. Int J Cancer 1990; 45: 654–660.
   Google Scholar
• Young C-F, Andrews PE, Montgomery BT, et al. Tissue-specific and hormonal regulation of human prostate-specific glandular kallikrein. Biochemistry 1992; 31: 818–824.
   Google Scholar
• Diamandis EP, Yousef GM, Luo I, et al. The new human kallikrein gene family: implications in carcinogenesis. Trends Endocrinol Metab 2000; 11: 54–60.
   Google Scholar
• Yousef GM, Obiezu CV, Luo LY, et al. Prostase/KLK-L1 is a new member of the human kallikrein gene family, is expressed in prostate and breast tissues, and is hormonally regulated. Cancer Res 1999; 59: 4252–6.
   Google Scholar
• Yousef GM, Scorilas A, Jung K, et al. Molecular cloning of the human kallikrein 15 gene (KLK15). Up-regulation in prostate cancer. J Biol Chem 2001; 276: 53–61.
   Google Scholar
• Hara M, Koyanagi Y, Inoue T, et al. Some physico-chemical characteristics of gamma-seminoprotein, an antigenic component specific for human seminal plasma. Jap J Legal Med 1971; 25: 322–324.
   Google Scholar
• Wang MC, Valenzuela LA, Murphy GP, et al. Purification of a human prostate specific antigen. Invest Urol 1979; 17: 159–163.
   Google Scholar
• Papsidero LD, Wang MC, Valenzuela LA, et al. A prostate antigen in sera of prostatic cancer patients. Cancer Res 1980; 40: 2428–2432.
   Google Scholar
• Wang MC, Papsidero LD, Kuriyama M, et al. Prostate antigen: A new potentional marker for prostatic cancer. Prostate 1981; 2: 89–96.
   Google Scholar
• Kuriyama M, Wang MC, Lee C-I, et al. Use of human prostate-specific antigen in monitoring prostate cancer. Cancer Res 1981; 41: 3874–3876.
   Google Scholar
• Lundwall A, Lilja H. Molecular cloning of human prostate specific antigen cDNA. FEBS Lett 1987; 214: 317–22.
   Google Scholar
• Schaller J, Akiyama K, Tsuda, R, et al. Isolation, characterization and amino-acid sequence of gamma-seminoprotein, a glycoprotein from human seminal plasma. Eur J Biochem 1987; 170: 111–120.
   Google Scholar
• Schulz, P, Stucka, R, Feldmann, H, et al. Sequence of a cDNA clone encompassing the complete mature human prostate specific antigen (PSA) and an unspliced leading sequence. Nucleic Acids Res 1988; 16: 6226.
   Google Scholar
• Belanger A, van Halbeek H, Graves HCB, et al. Molecular mass and carbohydrate structure of prostate specific antigen: studies for establishment of an international PSA standard. Prostate 1995; 27: 187–197.
   Google Scholar
• Kumar A, Mikolajczyk SD, Goel AS, et al. Expression of pro form of prostate-specific antigen by mammalian cells and its conversion to mature, active form by human kallikrein 2. Cancer Res 1997; 57: 3111–4.
   Google Scholar
• Lovgren J, Rajakoski K, Karp M, et al. Activation of the zymogen form of prostate-specific antigen by human glandular kallikrein 2. Biochem Biophys Res Commun 1997; 238: 54955.
   Google Scholar
• Takayama TK, Fujikawa K, Davie EW. Characterization of the precursor of prostate-specific antigen. Activation by trypsin and by human glandular kallikrein. J Biol Chem 1997; 272: 21582–8.
   Google Scholar
• Takayama TK, Carter CA, Deng T. Activation of prostate-specific antigen precursor (pro-PSA) by prostin, a novel human prostatic serine protease identified by degenerate PCR. Biochemistry 2001; 40: 1679–1687.
   Google Scholar
• Akiyama K, Nakamura T, Iwanaga S, et al. The chymotrypsin-like activity of human prostate-specific antigen, gamma-seminoprotein. FEBS Letter 1987; 225: 168–172.
   Google Scholar
• Lilja H, Abrahamsson PA, Lundwall A. Semenogelin, the predominant protein in human semen. Primary structure and identification of closely related proteins in the male accessory sex glands and on the spermatozoa. J Biol Chem 1989; 264: 1894–900.
   Google Scholar
• Christensson A, Laurell CB, Lilja H. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem 1990; 194: 755–63.
   Google Scholar
• Malm J, Hellman J, Lilja H. Characterization of the substrate specificity of prostate-specific antigen (PSA) by limited proteolysis of the major gel-proteins in human semen. Scand J Clin Lab Invest 1995; 55: Suppl 223 Abstract 544.
   Google Scholar
• Lilja H, Abrahamsson PA. Three predominant proteins secreted by the human prostate gland. Prostate 1988; 12: 29–38.
   Google Scholar
• Wang TJ, Rittenhouse HG, Wolfert RL, et al. PSA concentrations in seminal plasma. Clin Chem 1998; 44: 895a-896a.
   Google Scholar
• Lilja H, Laurell CB, Jeppsson JO. Characterization of the predominant basic protein in human seminal plasma, one cleavage product of the major seminal vesicle protein. Scand J Clin Lab Invest 1984; 44: 439–46.
   Google Scholar
• Lilja H. A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J Clin Invest 1985; 76: 1899–903.
   Google Scholar
• Lilja H, Oldbring J, Rannevik G, et al. Seminal vesicle-secreted proteins and their reactions during gelation and liquefaction of human semen. J Clin Invest 1987; 80: 2815.
   Google Scholar
• Lee C, Keefer M, Zhao ZW, et al. Demonstration of the roll of prostate-specific antigen in semen liquefaction by two-dimensional electrophoresis. J Androl 1989; 10: 432–438.
   Google Scholar
• McGee R, Herr J. Human seminal vesicle-specific antigen during semen liquefaction. Biol Reprod 1987; 37: 431–439.
   Google Scholar
• McGee R, Herr J. Human seminal vesicle-specific antigen is a substrate for prostate-specific antigen (or P-30). Biol Reprod 1988; 39: 499–510.
   Google Scholar
• Cohen P, Graves HCB, Peehl DM, et al. Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. J Clin Endocrinol Metab 1992; 74: 1046–1053.
   Google Scholar
• Iwamura M, di Sant'Agnese PA, Wu G, et al. Immunohistochemical localization of parathyroid hormone-related protein in human prostate cancer. Cancer Res 1993; 53: 1724–1726.
   Google Scholar
• Killian CS, Corral DA, Kawinski E, et al. Mitogenic response of osteoblast cells to prostate-specific antigen suggests an activation of latent TGF-beta and a proteolytic modulation of cell adhesion receptors. Biochem Biophys Res Commun 1993; 192: 940–947.
   Google Scholar
• Fortier AH, Nelson BJ, Grella DK, et al. Antiangiogenetic activity of prostate-specific antigen. J Natl Cancer Inst 1999; 91: 1635–1640.
   Google Scholar
• Stenman UH, Leinonen J, Alfthan H, et al. A complex between prostate-specific antigen and alpha-1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991; 51: 222–226.
   Google Scholar
• Lilja H, Christensson A, Dahlen U, et al. Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin Chem 1991; 37: 1618–25.
   Google Scholar
• Espana F, Sanchez-Cuenca J, Vera CD, et al. A quantative ELISA for the measurement of complexes of prostate-specific antigen with protein C inhibitor when using a purified standard. J Lab Clin Med 1993; 122: 711–719.
   Google Scholar
• Christensson A Lilja H. Complex formation between protein C inhibitor and prostate-specific antigen in vitro and in human semen. Eur J Biochem 1994; 220: 45–53.
   Google Scholar
• Heeb MJ, Espana F, Gittes RF, et al. Prostate specific antigen-alpha 2-macroglobulin complexes in prostate cancer patient sera. Biochem Mol Biol Int 1995; 37: 917–923.
   Google Scholar
• Otto A, Bar J, Birkenmeier G. Prostate-specific antigen forms complexes with human alpha2-macroglobulin and binds to the alpha2-macroblobulin receptor/lDL receptor-related protein. J Urol 1998; 159: 297–303.
   Google Scholar
• Zhang W-M, Finne P, Leinonen J, et al. Measurement of the complex between prostate-specific antigen and alpha-1-protease inhibitor in serum. Clin Chem 1999; 45: 814–821.
   Google Scholar
• Leinonen J, Zhang W-M, Stenman U-H. Complex formation between PSA isoenzymes and protease inhibitors. J Urol 1996; 155: 1099–1103.
   Google Scholar
• Watt K, Lee P-J, M'Timkulu T, et al. Human prostate-specific antigen: Structural and functional similarity with serine proteases. Proc Natl Acad Sci USA 1986; 83: 3166–3170.
   Google Scholar
• Zhang W-M, Finne P, Leinonen J, et al. Characterization and immunological determination of the complex between prostate-specific antigen and alpha-2-macroglobulin. Clin Chem 1998; 44: 2471–2479.
   Google Scholar
• Lilja H, Haese A, Bjork T, et al. Significance and metabolism of complexed and noncomplexed prostate specific antigen forms, and human glandular kallikrein 2 in clinically localized prostate cancer before and after radical prostatectomy. J Urol 1999; 162: 2029–34; discussion 2034–5.
   Google Scholar
• Carrell R, Travis J. Alpha-1-antitrypsin and the serpins: variation and countervariation. TIBS 1985; 10: 20–24.
   Google Scholar
• Sottrup-Jensen L. Alpha-macroglobulins: structure, shape, and mechanism of proteinase complex formation. J Biol Chem 1989; 264: 11539–11542.
   Google Scholar
• Mikolajczyk SD, Grauer LS, Millar LS, et al. A precursor form of PSA (pPSA) is a component of the free form of PSA in prostate cancer serum. Urology 1997; 50: 710–714.
   Google Scholar
• Noldus J, Chen Z, Stamey TA. Isolation and charcterization of free form prostate specific antigen (f-PSA) in sera of men with prostate cancer. J Urol 1997; 158: 1606–1609.
   Google Scholar
• Mikolajczyk SD, Millar LS, Wang TJ, et al. “BPSA”, a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia. Urology 2000; 55: 41–45.
   Google Scholar
• Nurmikko P, Vaisanen V, Piironen T, et al. Production and characterization of novel anti-prostate-specific antigen (PSA) monoclonal antibodies that do not detect internally cleaved Lys145-Lys146 inactive PSA. Clin Chem 2000; 46: 1610–8.
   Google Scholar
• Stamey TA, Yang N, Hay AR, et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987; 317: 909–916.
   Google Scholar
• Oesterling JE, Chan DW, Epstein JL, et al. Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J Urol 1988; 139: 766–772.
   Google Scholar
• Partin AW, Piantadosi S, Subong EN, et al. Clearance rate of serum-free and total PSA following radical retropubic prostatectomy. Prostate Suppl 1996; 7: 35–39.
   Google Scholar
• Bjork T, Ljungberg B, Piironen T, et al. Rapid exponential elimination of free prostate-specific antigen contrasts the slow, capacity-limited elimination of PSA complexed to alpha 1-antichymotrypsin from serum. Urology 1998; 51: 57–62.
   Google Scholar
• Birkenmeyer G, Struck F, Gebhardt R. Clearance mechanism of prostate specific antigen and its complexes with alpha2-macroglobulin and alpha1-antichymotrypsin. J Urol 1999; 162: 897–901.
   Google Scholar
• Kasza A, Petersen HH, Heegaard CW, et al. Specificity of serine proteinase/serpin complex binding to very-low-density lipoprotein receptor and alpha2-macroglobulin receptor/ low-density-lipoprotein-receptor-related protein. Eur J Biochem 1997; 248: 270–281.
   Google Scholar
• Pizzo SV, Mast AE, Feldman SR, et al. In vivo catabolism of alpha 1-antichymotrypsin is mediated by the serpin receptor which binds alpha 1-proteinase inhibitor, antithrombin III and heparin cofactor II. Biochim Biophys Acta 1988; 967: 158–162.
   Google Scholar
• Mast AE, Enghild JJ, Pizzo SV, et al. Analysis of the plasma elimination kinetics and conformational stabilities of native, proteinase-complexed, and reactive site cleaved serpins: comparison of alpha 1-antichymotrypsin, antithrombin III, alpha 2-antiplasmin, angiotensinogen, and ovalbumin. Biochemistry 1991; 30: 1723–1730.
   Google Scholar
• Zheng G, Bachinsky DR, Stamenkovic I, et al. Organ distribution in rats of two members of the low-density lipoprotein receptor gene family, gp 330 and LRP/alpha 2MR, and the receptor-associated protein (RAP). J Histochem Cytochem 1994; 42: 531–542.
   Google Scholar
• Poller W, Willnow TE, Hilpert J, et al. Differential recognition of alpha 1-antitrypsin-elastase and alpha 1-antichymotrypsin-cathepsin G complexes by the low density lipopro-tein receptor-related protein. J Biol Chem 1995; 270: 2841–2845.
   Google Scholar
• Oesterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991; 145: 907–923.
   Google Scholar
• Catalona WJ, Richie JP, Ahmann FR, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6630 men. J Urol 1994; 151: 1283–1290.
   Google Scholar
• Catalona WJ, Smith DS, Ornstein, DK. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/ml and benign prostate examination. JAMA 1997; 277: 1452–1455.
   Google Scholar
• Oesterling JE, Jacobsen SJ, Chute CG, et al. Serum prostate-specific antigen in a community based population of healthy men. Establishment of age-spcific reference ranges. JAMA 1993; 270: 860.
   Google Scholar
• Catalona WJ, Hudson MA, Scardino PT, et al. Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristics. J Urol 1994; 152: 2037–2042.
   Google Scholar
• Borer JG, Scherman J, Solomon MC, et al. Age specific prostate specific antigen reference ranges: population specific. J Urol 1998; 159: 444–448.
   Google Scholar
• Carter HB, Pearson JD, Metter EJ, et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostatic disease. JAMA 1992; 267: 2215–2220.
   Google Scholar
• Nixon RG, Wener MH, Smith KM, et al. Biological variation of prostate specific antigen levels in serum: an evaluation of day-to-day physiological fluctuations in a well-defined cohort of 24 patients. J Urol 1997; 157: 2183–2190.
   Google Scholar
• Benson MC, Whang IS, Pantuck A, et al. Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol 1992; 147: 815.
   Google Scholar
• Benson MC, Whang IS, Olsson CA, et al. The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J Urol 1992; 147: 817–821.
   Google Scholar
• Partin AW, Carter HB, Chan DW, et al. Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol 1990; 143: 747–752.
   Google Scholar
• Stamey TA, Kabalin JN, McNeil JE, et al. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy-treated patients. J Urol 1989; 141: 1076–1083.
   Google Scholar
• Zlotta AR, Djavan B, Marberger M, et al. Prostate specific antigen density of the transition zone: a new effective parameter for prostate cancer prediction. J Urol 1997; 157: 1315–1321.
   Google Scholar
• Djavan B, Zlotta AR, Byttebier G, et al. Prostate specific antigen density of the transition zone for early detection of prostate cancer. J Urol 1998; 160: 411–419.
   Google Scholar
• Christensson A, Bjork T, Nilsson O, et al. Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer. J Urol 1993; 150: 100–5.
   Google Scholar
• Bjartell A, Bjork T, Matikainen MT, et al. Production of alpha-1-antichymotrypsin by PSA-containing cells of human prostate epithelium. Urology 1993; 42: 502–10.
   Google Scholar
• Bjork T, Bjartell A, Abrahamsson PA, et al. Alpha 1-antichymotrypsin production in PSA-producing cells is common in prostate cancer but rare in benign prostatic hyperplasia. Urology 1994; 43: 427–34.
   Google Scholar
• Stephan K, Jung K, Brux B, et al. Molecular forms of prostate specific antigen (PSA) in malignant and benign prostatic tissue. J Urol 2000; 163: abstract # 1055.
   Google Scholar
• Catalona WJ, Smith DS, Wolfert RL, et al. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 1995; 274: 1214–1220.
   Google Scholar
• Luderer AA, Chen Y-T, Soriano TF, et al. Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen. Urology 1995; 46: 187–194.
   Google Scholar
• Vashi AR, Wojno KJ, Henricks W, et al. Determination of the “reflex range” and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system. Urology 1997; 49: 19–27.
   Google Scholar
• Veltri RW, Miller MC, Zhao G, et al. Evaluation of various molecular forms of PSA to distinguish benign prostatic hyperplasia (BPH) from prostate cancer (CaP). J Urol 1999; 161: abstract # 1231.
   Google Scholar
• Lein M, Jung K, Elgeti U, et al. Ratio of free and complexed to total prostate specific antigen in prostate cancer diagnosis. J Urol 2000; 163: abstract # 1231.
   Google Scholar
• Basso D, Fogar P, Piva MG, et al. Total PSA, free PSA/total PSA ratio, and molecular PSA detection in prostate cancer: which is clinically effective and when? Urology 2000; 55: 710.
   Google Scholar
• Djavan B, Remzi M, Seitz C, et al. Serum-PSA, F/T PSA, PSAD, PSA-TZ and PSA velocity: early detection of prostate cancer in men with serum PSA levels of 2.5 to 4.0 ng/ ml. J Urol 1999; 161: abstract #355.
   Google Scholar
• Hammerer P, Graefen M, Henke R-P, et al. Ratio of free/total PSA (%f-PSA) in men with serum PSA levels of 2.5-3 ng/ml: improvement for prostate cancer detection? J Urol 2000; 163: abstract #1230.
   Google Scholar
• Catalona WJ, Partin AW, Finlay JA, et al. Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when PSA levels are 2.51 to 4 ng/ ml and digital rectal examination is not suspicious for prostate cancer: an alternative model. Urology 1999; 54: 220–224.
   Google Scholar
• Partin AW, Catalona WJ, Finlay JA, et al. Use of human glandular kallikrein 2 for the detection of prostate cancer: preliminary analysis. Urology 1999; 54: 839–45.
   Google Scholar
• Sokoll LJ, Bruzek DJ, Dunn W, et al. Cancer detection rate for patients with total PSA concentrations < 4 ng/ml. J Urol 1999; 161: abstract #1227.
   Google Scholar
• Tornblom M, Norming U, Adolfsson J, et al. Diagnostic value of percent free prostate-specific antigen: retrospective analysis of a population-based screening study with emphasis on men with PSA levels less than 3.0 ng/ml. Urology 1999; 53: 945–50.
   Google Scholar
• Fowler JE, Sanders J, Bigler SA, et al. Percent free prostate specific antigen and cancer detection in black and white men with total prostate specific antigen 2.5 to 9.9 ng/ml. J Urol 2000; 163: 1467–1470.
   Google Scholar
• Catalona WJ, Partin AW, Slawin KM, et al. Use of percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998; 279: 1542–1547.
   Google Scholar
• Bangma CH, Kranse R, Blijenberg BG, et al. The value of screening tests in the detection of prostate cancer. Part II: retrospective analysis of free/total prostate-specific analysis ratio, age-specific reference ranges, and PSA density. Urology 1995; 46: 779.
   Google Scholar
• Schroder FH, van der Cruijsen-Koeter I, de Koening HJ, et al. Prostate cancer detection at low prostate specific antigen. J Urol 2000; 163: 806–812.
   Google Scholar
• Reissigl A, Klocker H, Pointner J, et al. Usefulness of the ratio free/total prostate-specific antigen in addition to total PSA levels in prostate cancer screening. Urology 1996; 48: 6266.
   Google Scholar
• Stein BS, Mirmirani S, Smithfield N. The economic effect of free PSA levels on the cost of screening for prostate cancer. J Urol 2000; 163: abstract #1228.
   Google Scholar
• Morgan TO, McLeod DG, Leifer ES, et al. Prospective use of free prostate-specific antigen to avoid repeat prostate biopsies in men with elevated total prostate-specific antigen. Urology 1996; 48: 76–80.
   Google Scholar
• Catalona WJ, Beiser JA, Smith DS. Serum free prostate specific antigen and prostate specific antigen density measurements for predicting cancer in men with prior negative biospies. J Urol 1997; 158: 2162–2167.
   Google Scholar
• Djavan B, Zlotta A, Remzi M, et al. Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1051 men. J Urol 2000; 163: 1144–1148.
   Google Scholar
• Stamey TA, Chen Z, Prestigiacomo A. Serum prostate specific antigen binding alpha-1-antichymotrypsin: influence of cancer volume, location and therapeutic selection of resistant clones. J Urol 1994; 152: 1510–1514.
   Google Scholar
• Lerner SE, Jacobsen SJ, Lilja H, et al. Free, complexed, and total serum prostate-specific antigen concentrations and their proportions in predicting stage, grade, and deoxyribo-nucleic acid ploidy in patients with adenocarcinoma of the prostate. Urology 1996; 48: 240–8.
   Google Scholar
• Pannek J, Subong EN, Jones KA, et al. The role of free/total prostate-specific antigen ratio in the predicition of final pathological stage for men with clinically localized prostate cancer. Urology 1996; 48: 6A:51-54.
   Google Scholar
• Bangma CH, Kranse R, Blijenberg BG, et al. The free-to-total serum prostate specific antigen ratio for staging prostate carcinoma. J Urol 1997; 157: 544–547.
   Google Scholar
• Noldus J, Graefen M, Huland E, et al. The value of the ratio of free-to-total prostate specific antigen for staging purposes in previously untreated prostate cancer. J Urol 1998; 159: 2004–2007.
   Google Scholar
• Southwick PC, Catalona WJ, Partin AW, et al. Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate-specific antigen: a prospective multicenter clinical trial. J Urol 1999; 162: 1346–1351.
   Google Scholar
• Arcangeli GC, Shephard DL, Smith DS, et al. Correlation of percent free PSA with pathologic features of prostatic carcinoma. J Urol 1996; 155: 415A.
   Google Scholar
• Grossklaus DJ, Shappell SB, Gautam S, et al. Correlation between percent free PSA and tumor volume in radical prostatectomy specimens. J Urol 2000; 163: abstract #1056.
   Google Scholar
• Epstein JI, Chan DW, Sokoll LJ, et al. Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. J Urol 1998; 2407–2411.
   Google Scholar
• Haese A, Graefen M, Noldus J, et al. Prostatic volume and ratio of free-to-total prostate specific antigen in patients with prostatic cancer or benign prostatic hyperplasia. J Urol 1997; 158: 2188–2192.
   Google Scholar
• Partin AW, Catalona WJ, Southwick PC, et al. Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume, and age. Urology 1996; 48: 55–61.
   Google Scholar
• Ornstein DK, Smith DS, Humphrey PA, et al. The effect of prostate volume, age, total prostate specific antigen level and acute inflammation on the percentage of free serum prostate specific antigen levels in men without clinically detectable prostate cancer. J Urol 1998; 159: 1234.
   Google Scholar
• Vashi AR, Wojno KJ, Vessella RL, et al. Percent free PSA correlates directly with patient age. J Urol 1997; 157: abstract # 432.
   Google Scholar
• Oesterling JE, Jacobsen SJ, Klee GG, et al. Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios. J Urol 1995; 154: 1090–5.
   Google Scholar
• Lein M, Koening FJK, McGovern FJ, et al. The percentage of free prostate specific antigen is an age-independent tumour marker for prostate cancer: establishment of reference ranges in a large population of healthy men. Br J Urol 1998; 82: 231236.
   Google Scholar
• Dalton DL. Elevated serum prostate-specific antigen due to acute bacterial prostatitis. Urology 1989; 33: 465.
   Google Scholar
• Fink K, Reissigl A, Horniger W, et al. Findings of percent free prostate specific antigen (%F-PSA) in acute and chronic prostatitis and comparison to organ confined prostate cancer. J Urol 1998; 159: abstract #896.
   Google Scholar
• Graefen M, Noldus J, Hammerer P, et al. A high ratio of free to total prostate specific antigen (F-PSA%) is predominant in biochemical relapse of prostate cancer (PCA) after radical prostatectomy (RP). J Urol 1997; 157: abstract #439.
   Google Scholar
• Vashi AR, Wojno KJ, Wright GL, et al. Percent free PSA values in men with recurrent cancer following radical prostatectomy question the hypothesis of percent-free PSA. J Urol 1998; 159: abstract #902.
   Google Scholar
• Lin DW, Noteboom JL, Blumenstein BA, et al. Serum percent free prostate-specific antigen in metastatic prostate cancer. Urology 1998; 52: 366–371.
   Google Scholar
• Piironen T, Pettersson K, Suonpaa M, et al. In vitro stability of free prostate-specific antigen (PSA) and prostate-specific antigen (PSA) complexed to alpha 1-antichymotrypsin in blood samples. Urology 1996; 48(6A): 81–7.
   Google Scholar
• Woodrum D, French C, Shamel LB. Stability of free prostate-specific antigen in serum samples under a variety of sample collection and sample storage conditions. Urology 1996; 48(6A): 33–39.
   Google Scholar
• Woodrum D, York L. Two-year stability of free and total PSA in frozen serum samples. Urology 1998; 52: 247–251.
   Google Scholar
• Leinonen J, Lovgren T, Vornanen T, et al. Double-label time-resolved immunofluorometric assay of prostate-specific antigen and of its complex with alpha-1-antichymotrypsin. Clin Chem 1993; 39: 2098–2103.
   Google Scholar
• Allard WJ, Zhou Z, Yeung KK. Novel immunoassay for the measurement of complexed prostate-specific antigen in serum. Clin Chem 1998; 44: 1216–1223.
   Google Scholar
• Finne P, Zhang W-M, Auvinen A, et al. Use of the complex between prostate-specific antigen and alpha1-protease inhibitor in screening for prostate cancer. J Urol 2000; 164: 1956–1960.
   Google Scholar
• Brawer MK, Meyer GE, Letran JL, et al. Measurement of complexed PSA improves specificity for early detection of prostate cancer. Urology 1998; 52: 372–378.
   Google Scholar
• Lynn NN, Collins GN, O'Reilly PH. Prostatic manipulation has a minimal effect on complexed prostate-specific antigen levels. BJU Int 2000; 86: 65–67.
   Google Scholar
• Lein M, Jung K, Hammerer P, et al. A multicenter clinical trial on the use of alpha1-antichymotrypsin-prostate-specific antigen in prostate cancer diagnosis. Prostate 2001; 47: 77–84.
   Google Scholar
• Stamey TA, Yemoto CE. Examination of the 3 molecular forms of serum prostate specific antigen for distinguishing negative from positive biopsy: relationship to transition zone volume. J Urol 2000; 163: 119–126.
   Google Scholar
• Brawer MK, Cheili CD, Neaman IE, et al. Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer. J Urol 2000; 163: 1476–1480.
   Google Scholar
• Okegawa T, Noda H, Nutahara K, et al. Comparison of two investigative assays for the complexed prostate-specific antigen in total prostate-specific antigen between 4.1 and 10.0 ng/ml. Urology 2000; 55: 700–704.
   Google Scholar
• Jung K, Elgeti U, Lein M, et al. Ratio of free or complexed prostate-specific antigen (PSA) to total PSA: Which ratio improves differentiation between benign prostatic hyperplasia and prostate cancer? Clin Chem 2000; 46: 55–62.
   Google Scholar
• Filella X, Alcover J, Molina R, et al. Measurement of complexed PSA in the differential diagnosis between prostate cancer and benign prostate hyperplasia. Prostate 2000; 42: 181–185.
   Google Scholar
• Maeda H, Arai Y, Aoki Y, et al. Complexed prostate-specific antigen and its volume indexes in the detection of prostate cancer. Urology 1999; 54: 225–228.
   Google Scholar
• Espana F, Royo M, Martinez M, et al. Free and complexed prostate specific antigen in the differentiation of benign prostatic hyperplasia and prostate cancer: studies in serum and plasma samples. J Urol 1998; 160: 2081–2088.
   Google Scholar
• Kuriyama M, Ueno K, Uno H, Akimoto S, et al. Clinical evaluation of serum prostate-specific antigen-alpha1-antichymotrypsin complex values in diagnosisi of prostate cancer a cooperative study. Int J Urol 1998; 5: 48–54.
   Google Scholar
• Morris BJ. hGK-1: A kallikrein gene expressed in human prostate. Clin Exp Pharmacol Physicol 1989; 16: 345–351.
   Google Scholar
• Deperthes D, Chapdelaine P, Tremblay, RR, et al. Isolation of prostatic kallikrein hK2, also known as hGK-1, in human seminal plasma. Biochim Biophys Acta 1995; 1245: 311–6.
   Google Scholar
• Darson MF, Pacelli A, Roche P, et al. Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker. Urology 1997; 49: 857–62.
   Google Scholar
• Darson MF, Pacelli A, Roche P, et al. Human glandular kallikrein 2 expression in prostate adenocarcinoma and lymph node metastases. Urology 1999; 53: 939–44.
   Google Scholar
• Lovgren J, Valtonen-Andre C, Marsal K, et al. Measurement of prostate-specific antigen and human glandular kallikrein 2 in different body fluids. J Androl 1999; 20: 348–55.
   Google Scholar
• Piironen T, Lovgren J, Karp M, et al. Immunofluorometric assay for sensitive and specific measurement of human prostatic glandular kallikrein (hK2) in serum. Clin Chem 1996; 42: 1034–41.
   Google Scholar
• Charlesworth MC, Young CY, Klee GG, et al. Detection of a prostate-specific protein, human glandular kallikrein (hK2), in sera of patients with elevated prostate-specific antigen levels. Urology 1997; 49: 487–93.
   Google Scholar
• Finlay JA, Evans CL, Day JR, et al. Development of monoclonal antibodies specific for human glandular kallikrein (hK2): development of a dual antibody immunoassay for hK2 with negligible prostate-specific antigen cross-reactivity. Urology 1998; 51: 804–9.
   Google Scholar
• Saedi MS, Hill TM, Kuus-Reichel K, et al. The precursor form of the human kallikrein 2, a kallikrein homologous to prostate-specific antigen, is present in human sera and is increased in prostate cancer and benign prostatic hyperplasia. Clin Chem 1998; 44: 21159.
   Google Scholar
• Kwiatkowski MK, Recker F, Piironen T, et al. In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic “gray zone” of total PSA 4 to 10 ng/ml. Urology 1998; 52: 360–5.
   Google Scholar
• Recker F, Kwiatkowski MK, Piironen T, et al. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma. Cancer 1998; 83: 2540–7.
   Google Scholar
• Klee GG, Goodmanson MK, Jacobsen SJ, et al. Highly sensitive automated chemiluminometric assay for measuring free human glandular kallikrein-2. Clin Chem 1999; 45: 800–6.
   Google Scholar
• Magklara A, Scorilas A, Catalona WJ, et al. The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA. Clin Chem 1999; 45: 1960–6.
   Google Scholar
• Becker C, Piironen T, Pettersson K, et al. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum. J Urol 2000; 163: 311–6.
   Google Scholar
• Becker C, Piironen T, Pettersson K, et al. Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/ml or greater. Urology 2000; 55: 694–9.
   Google Scholar
• Nam RK, Diamandis EP, Toi A, et al. Serum human glandular kallikrein-2 protease levels predict the presence of prostate cancer among men with elevated prostate-specific antigen. J Clin Oncol 2000; 18: 1036–42.
   Google Scholar
• Lovgren J, Piironen T, Overmo C, et al. Production of recombinant PSA and HK2 and analysis of their immunologic cross-reactivity. Biochem Biophys Res Commun 1995; 213: 888–95.
   Google Scholar
• Grauer LS, Charlesworth MC, Saedi MS, et al. Identification of human glandular kallikrein hK2 from LNCaP cells. J Androl 1996; 17: 353–9.
   Google Scholar
• Mikolajczyk SD, Millar LS, Kumar A, et al. Human glandular kallikrein, hK2, shows arginine-restricted specificity and forms complexes with plasma protease inhibitors. Prostate 1998; 34: 44–50.
   Google Scholar
• Mikolajczyk SD, Millar LS, Marker KM, et al. Ala217 is important for the catalytic function and autoactivation of prostate-specific human kallikrein 2. Eur J Biochem 1997; 246: 440–6.
   Google Scholar
• Lovgren J, Tian S, Lundwall, A et al. Production and activation of recombinant hK2 with propeptide mutations resulting in high expression levels. Eur J Biochem 1999; 266: 10505.
   Google Scholar
• Lovgren J, Airas K, Lilja H. Enzymatic action of human glandular kallikrein 2 (hK2). Substrate specificity and regulation by Zn2+ and extracellular protease inhibitors. Eur J Biochem 1999; 262: 781–9.
   Google Scholar
• Deperthes D, Frenette G, Brillard-Bourdet M, et al. Potential involvement of kallikrein hK2 in the hydrolysis of the human seminal vesicle proteins after ejaculation. J Androl 1996; 17: 659–65.
   Google Scholar
• Frenette G, Tremblay RR, Lazure C, et al. Prostatic kallikrein hK2, but not prostate-specific antigen (hK3), activates single-chain urokinase-type plasminogen activator. Int J Cancer 1997; 71: 897–9.
   Google Scholar
• Mikolajczyk SD, Millar LS, Kumar A, et al. Prostatic human kallikrein 2 inactivates and complexes with plasminogen activator inhibitor-1. Int J Cancer 1999; 81: 438–42.
   Google Scholar
• Charlesworth MC, Young CY, Miller VM, et al. Kininogenase activity of prostate-derived human glandular kallikrein (hK2) purified from seminal fluid. J Androl 1999; 20: 220–9.
   Google Scholar
• Bhoola KD, Figueroa CD, Worthy K. Bioregulation of kinins: kallikreins, kininogens, and kinases. Pharmacol Rev 1992; 44: 1–80.
   Google Scholar
• Heeb MJ, Espana F. alpha2-macroglobulin and C1-inactivator are plasma inhibitors of human glandular kallikrein. Blood Cells Mol Dis 1998; 24: 412–9.
   Google Scholar
• Grauer LS, Finlay JA, Mikolajczyk SD, et al. Detection of human glandular kallikrein, hK2, as its precursor form and in complex with protease inhibitors in prostate carcinoma serum. J Androl 1998; 19: 407–11.
   Google Scholar
• Mikolajczyk SD, Millar LS, Marker KM, et al. Identification of a novel complex between human kallikrein 2 and protease inhibitor-6 in prostate cancer tissue. Cancer Res 1999; 59: 3927–30.
   Google Scholar
• Black MH, Magklara A, Obiezu CV, et al. Development of an ultrasensitive immunoassay for human glandular kallikrein with no cross-reactivity from prostate-specific antigen. Clin Chem 1999; 45: 790–9.
   Google Scholar
• Becker C, Piironen T, Kiviniemi J, et al. Sensitive and specific immunodetection of human glandular kallikrein 2 in serum. Clin Chem 2000; 46: 198–206.
   Google Scholar
• Saedi MS, Cass MM, Goel AS, et al. Overexpression of a human prostate-specific glandular kallikrein, hK2, in E. coli and generation of antibodies. Mol Cell Endocrinol 1995; 109: 237–41.
   Google Scholar
• Kumar A, Goel AS, Hill TM, et al. Expression of human glandular kallikrein, hK2, in mammalian cells. Cancer Res 1996; 56: 5397–402.
   Google Scholar
• Eerola R, Piironen T, Pettersson K, et al. Immunoreactivity of recombinant human glandular kallikrein using monoclonal antibodies raised against prostate-specific antigen. Prostate 1997; 31: 84–90.
   Google Scholar
• Corey E, Buhler KR, Vessella RL. Cross-reactivity of ten anti-prostate-specific antigen monoclonal antibodies with human glandular kallikrein. Urology 1997; 50: 567–71; discussion 571–2.
   Google Scholar
• Finlay JA, Day JR, Rittenhouse HG. Polyclonal and monoclonal antibodies to prostate-specific antigen can cross-react with human kallikrein 2 and human kallikrein 1. Urology 1999; 53: 746–51.
   Google Scholar
• Haese A, Becker C, Noldus J, et al. Human glandular kallikrein 2: a potential serum marker for predicting the organ-confined versus non-organ-confined growth of prostate cancer. J Urol 2000; 163: 1491–7.
   Google Scholar
• Recker F, Kwiatkowski MK, Piironen T, et al. Human glandular kallikrein as a tool to improve discrimination of poorly differentiated and non-organ-confined prostate cancer compared with prostate-specific antigen. Urology 2000; 55: 481–5.
   Google Scholar
• Chu TM. Prostate-specific antigen and early detection of prostate cancer. Tumor Biol 1997; 18: 123–134.
   Google Scholar
• Sensabaugh GF. Isolation and characterization of a semen-specific protein from human seminal plasma: A potential new marker for semen identification. J Forensic Sci 1978; 23: 106–115.
   Google Scholar
• Yu H, Diamandis EP, Sutherland DJ. Immunoreactive prostate-specific antigen levels in female and male breast tumors and its association with steroid hormone receptors and patient age. Clin Biochem 1994; 27: 75–9.
   Google Scholar
• Diamandis EP, Yu H, Sutherland DJ. Detection of prostate-specific antigen immunoreac-tivity in breast tumors. Breast Cancer Res Treat 1994; 32: 301–10.
   Google Scholar
• Monne M, Croce CM, Yu H, et al. Molecular characterization of prostate-specific antigen messenger RNA expressed in breast tumors. Cancer Res 1994; 54: 6344–7.
   Google Scholar
• Yu H, Diamandis EP, Monne M, et al. Oral contraceptive-induced expression of prostate-specific antigen in the female breast. J Biol Chem 1995; 270: 6615–8.
   Google Scholar
• Magklara A, Cheung, CC, Asa SL, et al. Expression of prostate-specific antigen and human glandular kallikrein 2 in the thyroid gland. Clin Chim Acta 2000; 300: 171–80.
   Google Scholar
• Levesque M, Hu H, D'Costa M, et al. Prostate-specific antigen expression by various tumors. J Clin Lab Anal 1995; 9: 123–8.
   Google Scholar
• Zarghami N, Levesque M, D'Costa M, et al. Frequency of expression of prostate-specific antigen mRNA in lung tumors. Am J Clin Pathol 1997; 108: 184–90.
   Google Scholar
• Levesque M, Yu H, D'Costa M, et al. Immunoreactive prostate-specific antigen in lung tumors. J Clin Lab Anal 1995; 9: 375–9.
   Google Scholar
• Zarghami N, D'Costa M, Tsuyuki D, et al. Expression of the prostate specific antigen gene by lung tissue. Clin Cancer Res 1997; 3: 1201–6.
   Google Scholar
• McLachlin SM, Srigley JR. Prostatic tissue in mature cystic teratoma of the ovary. Am J Surg Pathol 1992; 16: 780–784.
   Google Scholar
• Buzzi A, Crescini C, Sonzogni A, et al. Prostatic tissue in a cystic teratoma of the ovary. Minerva Ginecol 1994; 46: 49–51.
   Google Scholar
• Yu H, Diamandis EP, Levesque M, et al. Expression of the prostate-specific antigen gene by a primary ovarian carcinoma. Cancer Res 1995; 55: 1603–6.
   Google Scholar
• Pollen JJ, Dreilinger A. Immunohistochemical identification of prostatic acid phosphatase and prostate specific antigen in female periurethral glands. Urology 1984; 23: 303–304.
   Google Scholar
• Tepper SL, Jigard J, Heath D, et al. Homology between the female paraurethral (Skene's) glands and the prostate. Immuno-histochemical demonstration. Arch Pathol Lab Med 1984; 108: 432–425.
   Google Scholar
• Wernert N, Albrecht M, Sesterhenn I, et al. The “female prostate”. Location, morphology, immunohistochemical characteristics and significance. Eur Urol 1992; 22: 64–69.
   Google Scholar
• Svanholm H, Andersen OP, Rohl, H. Tumor of female paraurethral duct. Immunohistochemical similarity with prostatic carcinoma. Virchows Arch A Pathol Anat Histopathol 1987; 411: 395–398.
   Google Scholar
• Spencer JR, Brodin AG, Ignatoff JM. Clear cell adenocarcinoma of the urethra: Evidence for origin within paraurethral ducts. J Urol 1990; 143: 122–125.
   Google Scholar
• Zaviacic M, Sidlo J, Borovsky, M. Prostate-specific antigen and prostate specific acid phosphatase in adenocarcinoma of the Skene's paraurethral glands and ducts. Virchows Arch A Pathol Anat Histopathol 1993; 423: 503–505.
   Google Scholar
• Ebisuno S, Miyai M, Tomofumi N. Clear cell adenocarcinoma of the female urethra showing positive staining with antibodies to prostate-specific antigen and prostatic acid phosphatase. Urology 1995; 45: 682–685.
   Google Scholar
• Frazier HA, Humphrey PA, Burchette JL, et al. Immunoreactive prostatic specific antigen in male periurethral glands. J Urol 1992; 147: 246–248.
   Google Scholar
• Papotti M, Paties C, Peveri V, et al. Immunocytochemical detection of prostate-specific antigen (PSA) in skin adnexal and breast tissues and tumors. Basic Appl Histochem 1989; 33: 25–29.
   Google Scholar
• Golz R, Schubert, GE. Prostatic-specific antigen. Immunoreactivity in urachal remnants. J Urol 1989; 141: 1480–1482.
   Google Scholar
• Minkowitts G, Peterson P, Godwin, TA. A histochemical and immunohistochemical study of adenocarcinomas involving urinary bladder. Mod Pathol 1990; 3: 68A.
   Google Scholar
• Grignon DJ, Ro JY, Ayala AG, et al. Primary adenocarcinoma of the urinary bladder: a clinico-pathologic analysis of 72 cases. Cancer 1991; 67: 2165–2172.
   Google Scholar
• Ishikawa, T, Kashiwagi, H, Iwakami, Y, et al. Expression of alpha-fetoprotein and prostate-specific antigen genes in several tissues and detection of mRNAs in normal circulating blood by reverse transcriptase-polymerase chain reaction. Jpn J Clin Oncol 1998; 28: 723728.
   Google Scholar
• Kamoshida S, Tsutsumi, Y. Extraprostatic localization of prostatic acid phosphatase and prostate-specific antigen: distribution in cloacogenic glandular epithelium and sex-dependent expression in human anal gland. Hum Pathol 1990; 21: 1108–1111.
   Google Scholar
• Van Krieken JH. Prostate marker immunoreactivity in salivary gland neoplasms. Am J Surg Path 1993; 17: 410–414.
   Google Scholar
• James GK, Pudek M, Berean KW, et al. Salivary duct carcinoma secreting prostate-specific antigen. Am J Clin Pathol 1996; 106: 242–7.
   Google Scholar
• Tazawa K, Kurihara Y, Kamoshida S, et al. Localization of prostate-specific antigen-like immunoreactivity in human salivary gland and salivary gland tumors. Pathol Int 1999; 49: 500–505.
   Google Scholar
• Elgamal AA, van de Voorde W, van Poppel H, et al. Immunohistochemical localization of prostate-specific markers within the accessory male gland of Cowper, Littre and Morgagni. Urology 1994; 44: 84–90.
   Google Scholar
• Clements J, Mukhtar A. Glandular kallikreins and prostate-specific antigen are expressed in the human endometrium. J Clin Endocrinol Metab 1994; 78: 1536–9.
   Google Scholar
• Smith MR, Biggar S, Hussain, M. Prostate-specific antigen messenger RNA is expressed in non-prostate cells: Implications for detection of micrometastases. Cancer Res 1995; 55: 2640–2644.
   Google Scholar
• Kuopio T, Ekfors TO, Nikkanen V, et al. Acinar cell carcinoma of the pancreas. Report of three cases. APMIS 1995; 103: 69–78.
   Google Scholar
• Pezzilli R, Bertaccini A, Billi P, et al. Serum prostate-specific antigen in pancreatic disease. Ital J Gastroenterol Hepatol 1999; 31: 580–583.
   Google Scholar
• Rittenhouse HG, Finlay JA, Mikolajczyk SD, et al. Human Kallikrein 2 (hK2) and prostate-specific antigen (PSA): two closely related, but distinct, kallikreins in the prostate. Crit Rev Clin Lab Sci 1998; 35: 275–368.
   Google Scholar
• Sauter ER, Daly M, Linahan K, et al. Prostate-specific antigen levels in nipple aspirate fluid correlate with breast cancer risk. Cancer Epidemiol Biomarkers Prev 1996; 5: 967–70.
   Google Scholar
• Magklara A, Scorilas A, Lopez-Otin C, et al. Human glandular kallikrein in breast milk, amniotic fluid, and breast cyst fluid. Clin Chem 1999; 45: 1774–80.
   Google Scholar
• Obiezu CV, Giltay EJ, Magklara A, et al. Dramatic suppression of plasma and urinary prostate specific antigen and human glandular kallikrein by antiandrogens in male-to-female transsexuals. J Urol 2000; 163: 802–5.
   Google Scholar
• Obiezu CV, Giltay EJ, Magklara A, et al. Serum and urinary prostate-specific antigen and urinary human glandular kallikrein concentrations are significantly increased after testosterone administration in female-to-male transsexuals. Clin Chem 2000; 46: 859–62.
   Google Scholar
• Yu H, Diamandis, EP. Prostate-specific antigen in milk of lactating women. Clin Chem 1995; 41: 54–8.
   Google Scholar
• Yu H, Diamandis EP. Prostate-specific antigen immunoreactivity in amniotic fluid. Clin Chem 1995; 41: 204–10.
   Google Scholar
• Melegos DN, Freedman MS, Diamandis EP. Prostate-specific antigen in cerebrospinal fluid. Clin Chem 1997; 43: 855.
   Google Scholar
• Yu H, Diamandis EP. Ultrasensitive time-resolved immunofluorometric assay of prostate-specific antigen in serum and preliminary clinical studies. Clin Chem 1993; 39: 2108–14.
   Google Scholar
• Black MH, Diamandis EP. The diagnostic and prognostic utility of prostate-specific antigen for diseases of the breast. Breast Cancer Res Treat 2000; 59: 1–14.
   Google Scholar
• Black MH, Magklara A, Obiezu C, et al. Expression of a prostate-associated protein, human glandular kallikrein (hK2), in breast tumours and in normal breast secretions. Br J Cancer 2000; 82: 361–7.
   Google Scholar
• Yu H, Diamandis EP, Zarghami N, et al. Induction of prostate specific antigen production by steroids and tamoxifen in breast cancer cell lines. Breast Cancer Res Treat 1994; 32: 291–300.
   Google Scholar
• Zarghami N, Grass L, Diamandis EP. Steroid hormone regulation of prostate-specific antigen gene expression in breast cancer. Br J Cancer 1997; 75: 579–88.
   Google Scholar
• Magklara A, Grass L, Diamandis, EP. Differential steroid hormone regulation of human glandular kallikrein (hK2) and prostate-specific antigen (PSA) in breast cancer cell lines. Breast Cancer Res Treat 2000; 59: 263–70.
   Google Scholar
• Cleutjens KBJM, van der Korput HAGM, van Eekelen CCEM, et al. An androgen response element in far upstream enhancer region is essential for high, androgen-regulated activity of the prostate-specific antigen promotor. Mol Endocrinol 1997; 11: 148–161.
   Google Scholar
• Diamandis EP. Prostate-specific antigen: a cancer fighter and a valuable messenger? Clin Chem 2000; 46: 896–900.
   Google Scholar
• Yu H, Diamandis EP. Measurement of serum prostate specific antigen levels in women and in prostatectomized men with an ultrasensitive immunoassay technique. J Urol 1995; 153: 1004–8.
   Google Scholar
• Ferguson RA, Yu H, Kalyvas M, et al. Ultrasensitive detection of prostate-specific antigen by a time-resolved immunofluorometric assay and the Immulite immunochemiluminescent third-generation assay: potential applications in prostate and breast cancers. Clin Chem 1996; 42: 675–84.
   Google Scholar
• Melegos DN, Diamandis EP. Is prostate-specific antigen present in female serum? Clin Chem 1998; 44: 691–2.
   Google Scholar
• Hautmann S, Huland E, Grupp C, et al. Super-sensitive prostate-specific antigen (PSA) in serum of women with benign breast disease or breast cancer. Anticancer Res 2000; 20: 2151–2154.
   Google Scholar
• Parish DC. Prostate-specific antigen in the breast. Endo-Rel Cancer 1998; 5: 223–229.
   Google Scholar
• Borchert GH, Giai M, Diamandis EP. Elevated levels of prostate-specific antigen in serum of women with fibroadenomas and breast cysts. J Natl Cancer Inst 1997; 89: 587–8.
   Google Scholar
• Yu H, Levesque MA, Clark GM, et al. Prognostic value of prostate-specific antigen for women with breast cancer: a large United States cohort study. Clin Cancer Res 1998; 4: 1489–97.
   Google Scholar
• Howarth DJ, Aronson IB, Diamandis EP. Immunohistochemical localization of prostate-specific antigen in benign and malignant breast tissues. Br J Cancer 1997; 75: 1646–51.
   Google Scholar
• Heyl W, Wolff JM, Biesterfeld S, et al. Immunohistochemical analysis of prostate-specific antigen does not correlate to other prognostic factors in breast cancer. Breast Cancer Res Treat 1999; 56: 169–176.
   Google Scholar
• Alanen KA, Kuopio T, Collan YU, et al. Immunohistochemical labelling for prostate-specific antigen in breast carcinomas. Breast Cancer Res Treat 1999; 56: 169–176.
   Google Scholar
• Hall RE, Clements JA, Birrell SN, et al. Prostate-specific antigen and gross cystic disease fluid protein-15 are co-expressed in androgen receptor-positive breast tumours. Br J Cancer 1998; 78: 360–5.
   Google Scholar
• Majumdar S, Diamandis EP. The promoter and the enhancer region of the KLK 3 (prostate specific antigen) gene is frequently mutated in breast tumours and in breast carcinoma cell lines. Br J Cancer 1999; 79: 1594–602.
   Google Scholar
• Foekens JA, Diamandis EP, Yu H, et al. Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer. Br J Cancer 1999; 79: 888–94.
   Google Scholar
• Kogan I, Ballinger JR, Redshaw R, et al. Prostate-specific antigen induction by a steroid hormone in T47D cells growing in SCID mice. Breast Cancer Res Treat 1998; 48: 73–80.
   Google Scholar
• Yu H, Diamandis EP, Levesque M, et al. Prostate specific antigen in breast cancer, benign breast disease and normal breast tissue. Breast Cancer Res Treat 1996; 40: 1718.
   Google Scholar
• Yu H, Giai M, Diamandis EP, et al. Prostate-specific antigen is a new favorable prognostic indicator for women with breast cancer. Cancer Res 1995; 55: 2104–10.
   Google Scholar
• Griniatsos J, Diamandis EP, Gioti J, et al. Correlation of prostate specific antigen immunoreactivity (IR-PSA) to other prognostic factors in female breast cancer. Anticancer Res 1998; 18: 683–688.
   Google Scholar
• Diamandis EP, Helle SI, Yu H, et al. Prognostic value of plasma prostate specific antigen after megestrol acetate treatment in patients with metastatic breast carcinoma. Cancer 1999; 85: 891–8.
   Google Scholar
• Diamandis EP. Elevated serum prostate-specific antigen levels in a woman with metastatic breast cancer. N Engl J Med 2000; 343: 890–1.
   Google Scholar
• Diamandis EP, Yu H, Lopez-Otin C. Prostate specific antigen—a new constituent of breast cyst fluid. Breast Cancer Res Treat 1996; 38: 259–64.
   Google Scholar
• Borchert GH, Yu H, Tomlinson G, et al. Prostate specific antigen molecular forms in breast cyst fluid and serum of women with fibrocystic breast disease. J Clin Lab Anal 1999; 13: 75–81.
   Google Scholar
• Lai LC, Erbas H, Lennard TW, et al. Prostate-specific antigen in breast cyst fluid: possible role of prostate-specific antigen in hormone-dependent breast cancer. Int J Cancer 1996; 66: 743–746.
   Google Scholar
• Mannello F, Bocchiotti G, Bianchi G, et al. Quantification of prostate-specific antigen immunoreactivity in human breast cyst fluuids. Breast Cancer Res Treat 1996; 38: 247252.
   Google Scholar
• Filella X, Molina R, Alcover J, et al. Prostate-specific antigen detection by ultrasensitive assay in samples from women. Prostate 1996; 29: 311–316.
   Google Scholar
• Malatesta M, Mannello F, Sebastiani M, et al. Prostate-specific antigen found in type I breast cyst fluids is a secretory product of apocrine cells lining breast gross cysts. Breast Cancer Res Treat 1999; 57: 157–163.
   Google Scholar
• Sauter ER, Babb J, Daly M, et al. Prostate-specific antigen production in the female breast: association with progesterone. Cancer Epidemiol Biomarkers Prev 1998; 7: 315–20.
   Google Scholar
• Foretova L, Garber JE, Sadowsky NL, et al. Prostate-specific antigen in nipple aspirates. Lancet 1996; 347: 1631.
   Google Scholar
• Zarghami N, Grass L, Sauter ER, et al. Prostate-specific antigen in serum during the menstrual cycle. Clin Chem 1997; 43: 1862–7.
   Google Scholar
• Melegos DN, Yu H, Allen LC, et al. Prostate-specific antigen in amniotic fluid of normal and abnormal pregnancies. Clin Biochem 1996; 29: 555–62.
   Google Scholar
• Randell EW, Diamandis EP, Ellis G. Serum prostate-specific antigen measured in children from birth to age 18 years. Clin Chem 1996; 42: 420–3.
   Google Scholar
• Borchert GH, Melegos DN, Tomlinson G, et al. Molecular forms of prostate-specific antigen in the serum of women with benign and malignant breast diseases. Br J Cancer 1997; 76: 1087–94.
   Google Scholar
• Black MH, Giai M, Ponzone R, et al. Serum total and free prostate-specific antigen for breast cancer diagnosis in women. Clin Cancer Res 2000; 6: 467–73.
   Google Scholar
• Melegos DN, Yu H, Ashok M, et al. Prostate-specific antigen in female serum, a potential new marker of androgen excess. J Clin Endocrinol Metab 1997; 82: 777–80.
   Google Scholar
• Escobar-Morreale HF, Serrano-Gotarredona J, Avita S, et al. The increased circulating prostate-specific antigen concentrations in women with hirsutism do not respond to acute changes in adrenal or ovarian function. J Clin Endocrinol Metab 1998; 83: 2580–2584.
   Google Scholar
• Escobar-Morreale HF, Avila S, Sancho J. Serum prostate-specific antigen concentrations are not useful for monitoring the treatment of hirsutism with oral contraceptive pills. J Clin Endocrinol Metab 2000; 85: 2488–2492.
   Google Scholar
• Lehrer S, Terk M, Piccoli SP, et al. Reverse transcriptase-polymerase chain reaction for prostate specific antigen may be a prognostic indicator in breast cancer. Br J Cancer 1996; 74: 871–873.
   Google Scholar
• Diamandis, EP. Prostate cancer, prostate-specific antigen, and the polymerase chain reaction. Clin Chem 1995; 41: 177–9.
   Google Scholar
• Ooka M, Sakita I, Fujiwara Y, et al. Selection of mRNA markers for detection of lymph node micrometastases in breast cancer patients. Oncol Rep 2000; 7: 561–566.
   Google Scholar
• Wolff JM, Heyl W, Borchers H, et al. Detection of prostate-specific antigen immunoreactivity in amniotic fluid. Urol Int 1999; 62: 139–142.
   Google Scholar
• Lambert-Messerlian GM, Canick JA, Melegos DN, et al. Increased concentrations of prostate-specific antigen in maternal serum from pregnancies affected by fetal Down syndrome. Clin Chem 1998; 44: 205–8.
   Google Scholar
• Wald NJ, Hackshaw AK, Diamandis EP, et al. Maternal serum prostate-specific antigen and Down syndrome in the first and second trimesters of pregnancy. International Prenatal Screening Research Group. Prenat Diagn 1999; 19: 674–6.
   Google Scholar
• Spencer K, Carpenter P. Is prostate specific antigen a marker for pregnancies affected by Down syndrome? Clin Chem 1998; 44: 2362–2365.
   Google Scholar